EP0491888A4 - Immunotherapeutic compositions for treating and preventing aids, arc and hiv infection - Google Patents

Immunotherapeutic compositions for treating and preventing aids, arc and hiv infection

Info

Publication number
EP0491888A4
EP0491888A4 EP19910910648 EP91910648A EP0491888A4 EP 0491888 A4 EP0491888 A4 EP 0491888A4 EP 19910910648 EP19910910648 EP 19910910648 EP 91910648 A EP91910648 A EP 91910648A EP 0491888 A4 EP0491888 A4 EP 0491888A4
Authority
EP
European Patent Office
Prior art keywords
human
prophylactic
treating
useful
immunotherapeutic
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP19910910648
Other languages
English (en)
Other versions
EP0491888A1 (fr
Inventor
Richard A. Fisher
Catherine Hession
Linda C. Burkly
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Biogen Inc
Original Assignee
Biogen Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Biogen Inc filed Critical Biogen Inc
Publication of EP0491888A1 publication Critical patent/EP0491888A1/fr
Publication of EP0491888A4 publication Critical patent/EP0491888A4/en
Withdrawn legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/70—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving virus or bacteriophage
    • C12Q1/701—Specific hybridization probes
    • C12Q1/702—Specific hybridization probes for retroviruses
    • C12Q1/703—Viruses associated with AIDS
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K67/00—Rearing or breeding animals, not otherwise provided for; New or modified breeds of animals
    • A01K67/027—New or modified breeds of vertebrates
    • A01K67/0275—Genetically modified vertebrates, e.g. transgenic
    • A01K67/0278—Knock-in vertebrates, e.g. humanised vertebrates
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/70514—CD4
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2812—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD4
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/8509—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells for producing genetically modified animals, e.g. transgenic
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2207/00—Modified animals
    • A01K2207/15—Humanized animals
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2217/00—Genetically modified animals
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2227/00—Animals characterised by species
    • A01K2227/10—Mammal
    • A01K2227/105—Murine
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2267/00—Animals characterised by purpose
    • A01K2267/03—Animal model, e.g. for test or diseases
    • A01K2267/0337—Animal models for infectious diseases
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2830/00—Vector systems having a special element relevant for transcription
    • C12N2830/008—Vector systems having a special element relevant for transcription cell type or tissue specific enhancer/promoter combination

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Virology (AREA)
  • Microbiology (AREA)
  • Environmental Sciences (AREA)
  • Biomedical Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Analytical Chemistry (AREA)
  • Biodiversity & Conservation Biology (AREA)
  • Animal Husbandry (AREA)
  • AIDS & HIV (AREA)
  • Plant Pathology (AREA)
  • Cell Biology (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Compositions immunothérapeutiques, prophylactiques et diagnostiques utilisées dans le traitement ou la prévention de maladies chez l'homme provoquées par des agents infectieux dont les cibles primaires sont les lymphocytes T4+, comprenant les infections du syndrome d'immunodéficience acquise, du complexe apparenté au SIDA et du virus d'immunodéficience humaine. L'invention concerne également des séquences d'ADN codant des variantes d'acide aminé ainsi que des dérivés de CD4 humaine, ou des fragments de ceux-ci, apparaissant dans des anticorps humains se liant à la gp120 du VIH. Lesdites séquences d'ADN sont utiles dans les compositions immunothérapeutiques, prophylactiques et diagnostiques de l'invention. De plus, l'invention concerne un nouveau procédé de triage permettant de sélectionner des variantes d'acide aminé ainsi que des dérivés de CD4 humaine apparaissant dans des anticorps humains se liant à la gp120 du VIH, la CD4 humaine ou les deux, utilisés comme agents thérapeutiques, prophylactiques et diagnostiques contre des maladies provoquées par des agents infectieux dont les cibles primaires sont les lymphocytes T4+, comprenant les infections dues au syndrome d'immunodéficience acquise, au complexe apparenté au SIDA et au virus d'immunodéficience humaine.
EP19910910648 1990-05-25 1991-05-23 Immunotherapeutic compositions for treating and preventing aids, arc and hiv infection Withdrawn EP0491888A4 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US52918690A 1990-05-25 1990-05-25
US529186 1990-05-25

Publications (2)

Publication Number Publication Date
EP0491888A1 EP0491888A1 (fr) 1992-07-01
EP0491888A4 true EP0491888A4 (en) 1992-09-02

Family

ID=24108870

Family Applications (1)

Application Number Title Priority Date Filing Date
EP19910910648 Withdrawn EP0491888A4 (en) 1990-05-25 1991-05-23 Immunotherapeutic compositions for treating and preventing aids, arc and hiv infection

Country Status (6)

Country Link
EP (1) EP0491888A4 (fr)
JP (1) JPH05502166A (fr)
AU (1) AU7976791A (fr)
CA (1) CA2062758A1 (fr)
OA (1) OA09648A (fr)
WO (1) WO1991018618A2 (fr)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2692435A1 (fr) * 1992-06-19 1993-12-24 Transgene Sa Lapin transgénique sensible au HIV, son usage à titre de modèle animal et son procédé d'obtention.
FR2696188A1 (fr) * 1992-09-25 1994-04-01 Curie Paris Vi Univ Pierre Mar Molécule CD4 de chat, séquence nucléique codant pour cette molécule et leurs applications.
WO2003072750A2 (fr) * 2002-02-27 2003-09-04 Prodigene, Inc. Expression de proteines liees au vih dans les plantes
US10150970B2 (en) 2011-07-27 2018-12-11 Applied Biotechnology Institute, Inc. Methods to increase antigenicity of membrane-bound polypeptides produced in plants

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1989001940A1 (fr) * 1987-09-04 1989-03-09 Biogen, Inc. Sequences d'adn, molecules d'adn recombinant et procedes de production de proteines t4 solubles
EP0330227A2 (fr) * 1988-02-24 1989-08-30 The Trustees Of Columbia University In The City Of New York Dérivés de T-4 solubles

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1989001940A1 (fr) * 1987-09-04 1989-03-09 Biogen, Inc. Sequences d'adn, molecules d'adn recombinant et procedes de production de proteines t4 solubles
EP0330227A2 (fr) * 1988-02-24 1989-08-30 The Trustees Of Columbia University In The City Of New York Dérivés de T-4 solubles

Non-Patent Citations (6)

* Cited by examiner, † Cited by third party
Title
@ the whole do *
CELL. vol. 60, 9 Mar *
MOLECULAR BIOLOGY AND MEDECINE vol. 6, September 1989, ACADEMIC PRESS pages 255 - 261; YU, S. ET AL.: 'fun *
SCIENCE. vol. 240, 10 June 1988, LANCASTER, PA US pages 1468 - 1474; JAENISH, R.: 'Transgeni *
SCIENTIFIC AMERICAN O *
THE JOURNAL OF EXPERIMENTAL MEDECINE vol. 170, O *

Also Published As

Publication number Publication date
WO1991018618A3 (fr) 1992-04-16
OA09648A (en) 1993-05-15
CA2062758A1 (fr) 1991-11-26
EP0491888A1 (fr) 1992-07-01
JPH05502166A (ja) 1993-04-22
AU7976791A (en) 1991-12-31
WO1991018618A2 (fr) 1991-12-12

Similar Documents

Publication Publication Date Title
CA2073031A1 (fr) Homologues d'anticorps anti-cd4 utilises a titre prophylactique et dans le traitement du sida, du para-sida et des infections par le vih
WO2002020554A3 (fr) Peptides vih, antigenes, compositions de vaccin, coffret de dosage immunologique et procede permettant la detection d'anticorps induits par vih
CA2082948A1 (fr) Peptides et anticorps immunogenes et leurs utilisations pour la fixation au recepteur des cd4
ES2013346A6 (es) Metodos para producir secuencias y moleculas de adn recombinante, asi como proteinas t4 solubles.
PT1159298E (pt) Péptidos de hiv, antigénios, composições de vacinas, kit de imunoensaio e um método de detecção de anticorpos induzidos por hiv
PT81338A (en) Antigens particularly envelope antigens of the virus of lymphadenopathies and of the acquired immuno-depressive syndrome and virus process for producing virus envelope antigens in the preparation of immunogenic compositions or for the diagnosis of the presence of antibodies against this virus
AU8083594A (en) Synthetic human neutralizing monoclonal antibodies to human immunodeficiency virus
EP0328403A3 (fr) Peptides synthétiques relatifs à la protéine HIV-GP120-env. et leur application
WO1991009872A3 (fr) Polypeptides selectivement reactifs avec des anticorps contre le virus d'immunodeficience humaine et vaccins comprenant les polypeptides
KR930702509A (ko) 사람 면역결핍 바이러스(hiv)면역치료제
WO2002020555A3 (fr) Peptides regulateurs et auxiliaires de vih, antigenes, compositions de vaccin, trousses de dosage immunologique et procede de detection d'anticorps induits par vih
WO1991018618A3 (fr) Compositions immunotherapeutiques de traitement et de prevention d'infections dues au sida, au para-sida et au vih
CA2057612A1 (fr) Peptides selectionnes de l'antigene specifique au groupe (gag) du virus de l'immunodeficience humaine (vih), sa preparation et son utilisation
CA2160696A1 (fr) Peptides utiles pour la vaccination et l'induction d'anticorps neutralisateurs contre le virus de l'immunodefience humaine
WO2003089000A3 (fr) Composition anti-vih, comprenant un polyanion et un agent agissant sur gp120 de acon equivalent au cd4
EP1104770A3 (fr) Compositions et procédés pour déceler et traiter le syndrome immunodéficitaire acquis
AU651113B2 (en) HIV GP120 monoclonal antibodies
WO2002034909A3 (fr) Chimere de fragments de proteines synthetisee et ses methodes d'utilisation
KR100871455B1 (ko) Ｈｉｖ 바이러스에 대한 천연 항체
EP0218431A3 (en) Novel polypeptides, dnas that code for the same and method of preparing said polypeptides and dnas
WO2002026253A1 (fr) Vaccin contre le sida, son procede de preparation et ses applications
FR2646607B1 (fr) Anticorps monoclonaux anti-b2 microglobuline
AU627540B2 (en) Drug for the treatment or prevention by passive immunization, of the hiv-infection and process for preparation thereof
CA2046016A1 (fr) Anticorps monoclonal du vih

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AT BE CH DE DK ES FR GB GR IT LI LU NL SE

17P Request for examination filed

Effective date: 19920612

A4 Supplementary search report drawn up and despatched

Effective date: 19920714

AK Designated contracting states

Kind code of ref document: A4

Designated state(s): AT BE CH DE DK ES FR GB GR IT LI LU NL SE

18W Application withdrawn

Withdrawal date: 19921222

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION HAS BEEN WITHDRAWN

R18W Application withdrawn (corrected)

Effective date: 19921222